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Background: Studies have demonstrated that systolic heart failure (HF) patients with the variant Ser49Gly have a better 5-year survival rate, and 
reduced mortality under beta-blocker therapy. However, the influence of the polymorphism Ser49Gly in heart failure adrenergic activation is still 
unknown. Our aim was to evaluate the relationship of cardiac adrenergic activation by I123-Metaiodobenzylganidine (MIBG) scintigraphy, before and 
after carvedilol treatment, with Ser49Gly polymorphism of beta-1 adrenergic receptor.
methods: Using a longitudinal prospective design, 28 patients were recruited from our Heart Failure Clinic between July 2006 and March 2008. 
Inclusion criteria were: presence of Heart Failure by Framinghan Criteria, NYHA class I-IV, age 30-80 years, left ventricular ejection fraction <45% 
(Simpson by echocardiogram) confirmed by MUGA, and no previous beta-blocker treatment. Myocardial scintigraphy with I123-MIBG and genotypic 
evaluation were performed. Revaluation scintigraphy was done after 3 months.
results: From 28 patients, 18 were males (64%), and overall mean age was 57.5 years. Ten patients (35.7%) were in class II (NYHA) and 18 
(64.3%) in class III. On admission, the mean LVEF was 28%. Regarding the genotypic profile, 12 patients were homozygous Ser49Ser and 16 patients 
presented the variant Gly49. The group with Gly49A variant showed, on MIBG washout rate, a significantly higher reduction after 3 months carvedilol 
treatment compared to the homozygous group (Gly49: -10% vs. Ser49Ser: +28%, p= 0.038). There were no differences on early and late heart/
mediastinum ratios between groups.
conclusion: Polymorphism Ser49Gly of B1- adrenoreceptor was associated with a better autonomic response to carvedilol treatment. Cardiac 
innervation as assessed by MIBG scintigraphy can detect distinct response profile to beta-blocker therapy.
